New Data Presented At WCTRIMS Supports The Importance Of Early And Sustained Treatment With Betaseron(R) Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron(R) (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment.
Source: www.medicalnewstoday.comCongressional Resolution Aims To Designate October As American Pharmacists Month (APhM) The American Pharmacists Association (APhA) applauds Rep. Marion Berry for introducing a House resolution (H.Res.1437) that would designate October as American Pharmacists Month (APhM).
Source: www.medicalnewstoday.comMulti Pronged Therapeutic Cancer Vaccine Regimen To Be Studied In Melanoma Patients Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced that it is sponsoring a Phase II clinical study exploring a multi-pronged treatment approach to high risk and advanced-stage melanoma -- an often fatal form of cancer for which there are limited treatment options. Patients are being enrolled in the United States and Canada.
Source: www.medicalnewstoday.comSuccessful Results For Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for triggering mucosal protection. The results significantly exceed the Industry standard of 60% to 70% effectiveness to be considered as a promising vaccine as well as of Mymetics' expectation which was considerable above this level.
Source: www.medicalnewstoday.comRepligen Announces Publication Of Positive Results With Proprietary HDAC Inhibitor In Huntington's Disease Model Repligen Corporation (Nasdaq: RGEN) reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.
Source: www.medicalnewstoday.comEnobia Pharma Receives FDA Orphan Drug Designation For Hypophosphatasia Product Candidate ENB-0040 Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for ENB-0040, its enzyme replacement therapy (ERT) for hypophosphatasia, a rare, life-threatening genetic bone disease. In August 2008, Enobia dosed the first patient in a Phase I clinical trial of ENB-0040.
Source: www.medicalnewstoday.comNovavax Commences Clinical Testing Of Its Seasonal Influenza VLP Vaccine Candidate Novavax, Inc. (Nasdaq: NVAX) announced vaccination of
healthy volunteers in a Phase II clinical trial of its virus-like particle (VLP) based seasonal influenza vaccine. The Phase IIa randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza VLP vaccine.
Source: www.medicalnewstoday.comBioSpecifics Technologies Corp. Announces Initiation Of Phase IIb Trial For Peyronie's Disease BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, announced the initiation of a U.S. Phase IIb clinical trial in Peyronie's disease for its injectable collagenase, XIAFLEX (TM), by its partner Auxlium Pharmaceuticals, Inc.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
